Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Aminolevulinic acid
Drug ID BADD_D00110
Description A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Indications and Usage Aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
Marketing Status approved
ATC Code L01XD04
DrugBank ID DB00855
KEGG ID D07567
MeSH ID D000622
PubChem ID 137
TTD Drug ID D0Y7ZD
NDC Product Code 46016-5450
UNII 88755TAZ87
Synonyms Aminolevulinic Acid | Acid, Aminolevulinic | Delta-Aminolevulinic Acid | Acid, Delta-Aminolevulinic | Delta Aminolevulinic Acid | Levulan | 5-Aminolaevulinate | 5 Aminolaevulinate | 5-Aminolevulinate | 5 Aminolevulinate | Aminolevulinic Acid Hydrochloride | Acid Hydrochloride, Aminolevulinic | Hydrochloride, Aminolevulinic Acid
Chemical Information
Molecular Formula C5H9NO3
CAS Registry Number 106-60-5
SMILES C(CC(=O)O)C(=O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acne23.02.01.001---
Alanine aminotransferase increased13.03.04.005--
Amnesia17.03.02.001; 19.20.01.0010.000112%
Amylase increased13.05.01.009--
Anaemia01.03.02.001--
Aphasia17.02.03.001; 19.21.01.001--
Application site erythema08.02.01.001; 12.07.01.001; 23.03.06.0050.004164%-
Application site irritation08.02.01.003; 12.07.01.0030.000381%-
Application site oedema08.02.01.020; 12.07.01.0200.000381%-
Application site pain08.02.01.004; 12.07.01.0040.003481%-
Application site pruritus08.02.01.005; 12.07.01.005; 23.03.12.0040.000571%-
Application site reaction08.02.01.006; 12.07.01.0060.000571%-
Application site warmth08.02.01.029; 12.07.01.0290.000381%-
Aspartate aminotransferase increased13.03.04.011--
Basal cell carcinoma16.03.02.001; 23.08.02.0010.000224%-
Blister12.01.06.002; 23.03.01.0010.000381%-
Blood bilirubin increased13.03.04.018--
Body temperature increased13.15.01.001---
Burning sensation08.01.09.029; 17.02.06.0010.000246%-
Chills08.01.09.001; 15.05.03.016--
Dermatitis23.03.04.002---
Dermatitis atopic10.01.04.004; 23.03.04.0160.001142%-
Diarrhoea07.02.01.001--
Discomfort08.01.08.003---
Drug ineffective08.06.01.0060.005003%-
Dry skin23.03.03.001--
Dysaesthesia17.02.06.003; 23.03.03.077--
Embolism venous24.01.01.003---
Erythema23.03.06.0010.001007%-
Eye disorder06.08.03.001---
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene